biostudies-literatureWeng JKNational Cancer InstituteNCI NIH HHSConquer Cancer FoundationCancer Prevention and Research Institute of Texas360-370https://www.ebi.ac.uk/biostudies/studies/S-EPMC9057640biostudies-literatureUnknown111(2)<h4>Purpose</h4>There are limited prospective data on predictors of patient-reported outcomes (PROs) after whole-breast irradiation (WBI) plus a boost. We sought to characterize longitudinal PROs and cosmesis in a randomized trial comparing conventionally fractionated (CF) versus hypofractionated (HF) WBI.<h4>Methods and materials</h4>From 2011 to 2014, women aged ≥40 years with Tis-T2 N0-N1a M0 breast cancer who underwent a lumpectomy with negative margins were randomized to CF-WBI (50 Gray [Gy]/25 fractions plus boost) versus HF-WBI (42.56 Gy/16 fractions plus boost). At baseline (pre-radiation), at 6 months, and yearly thereafter through 5 years, PROs included the Breast Cancer Treatment Outcome Scale (BCTOS), Functional Assessment of Cancer Therapy-Breast (FACT-B), and Body Image ScaleInternational journal of radiation oncology, biology, physicsFive-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation.PMC9057640R01 CA207216P30 CA016672R21 CA252411R01 CA225646R01 CA201487Tereffe WHortobagyi GNShaitelman SFStrom EAHunt KKHoffman KSchlembach PBloom ESArzu IYWeng JKWoodward WABuchholz TAGrade ELei XPerkins GReed VKChronowski GSmith BDShah SJDvorak TStauder MCfalseFive-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation.<h4>Purpose</h4>There are limited prospective data on predictors of patient-reported outcomes (PROs) after whole-breast irradiation (WBI) plus a boost. We sought to characterize longitudinal PROs and cosmesis in a randomized trial comparing conventionally fractionated (CF) versus hypofractionated (HF) WBI.<h4>Methods and materials</h4>From 2011 to 2014, women aged ≥40 years with Tis-T2 N0-N1a M0 breast cancer who underwent a lumpectomy with negative margins were randomized to CF-WBI (50 Gray [Gy]/25 fractions plus boost) versus HF-WBI (42.56 Gy/16 fractions plus boost). At baseline (pre-radiation), at 6 months, and yearly thereafter through 5 years, PROs included the Breast Cancer Treatment Outcome Scale (BCTOS), Functional Assessment of Cancer Therapy-Breast (FACT-B), and Body Image Scale2021-01-01T00:00:00Z2021 Oct2026-06-01T02:24:35.689Z2026-04-08T09:15:23.37ZS-EPMC90576403399271810.1016/j.ijrobp.2021.05.004